CRIS · Insider Trading
Curis Inc
Every open-market purchase and sale reported by CRIS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-09 | James E Dentzer | President & CEO | A | +110,090 deriv. | — |
| 2026-07-09 | Diantha Duvall | CFO | A | +48,285 deriv. | — |
| 2026-07-09 | Anne Elizabeth Borgman | Director | A | +6,800 deriv. | — |
| 2026-07-09 | Kenneth I Kaitin | Director | A | +6,800 deriv. | — |
| 2026-07-09 | Jonathan B. Zung | CDO | A | +48,285 deriv. | — |
| 2026-07-09 | John Hohneker | Director | A | +6,800 deriv. | — |
| 2026-07-09 | Marc Rubin | Director | A | +6,800 deriv. | — |
| 2026-07-09 | Martyn D Greenacre | Director | A | +6,800 deriv. | — |
| 2026-04-01 | Kenneth I Kaitin | Director | Buy | +10,000 | +$5.49K |
| 2026-03-23 | James E Dentzer | President & CEO | C | +133,333 | — |
| 2026-03-23 | Jonathan B. Zung | CDO | C | +66,667 | — |
| 2026-03-23 | Marc Rubin | Director | C | +26,667 | — |
| 2026-03-23 | Diantha Duvall | CFO | C | +66,666 | — |
| 2026-03-23 | Ahmed MD Hamdy | CMO | C | +66,667 | — |
| 2026-03-18 | Ahmed MD Hamdy | CMO | A | +200,051 deriv. | — |
| 2026-03-18 | Diantha Duvall | CFO | A | +200,048 deriv. | — |
| 2026-03-18 | Marc Rubin | Director | A | +80,021 deriv. | — |
| 2026-03-18 | James E Dentzer | President & CEO | A | +400,099 deriv. | — |
| 2026-03-18 | Jonathan B. Zung | CDO | A | +200,051 deriv. | — |
| 2025-05-22 | Martyn D Greenacre | Director | A | +14,400 deriv. | — |
| 2025-05-22 | Kenneth I Kaitin | Director | A | +14,400 deriv. | — |
| 2025-05-22 | James E Dentzer | President & CEO | A | +360,000 deriv. | — |
| 2025-05-22 | Jonathan B. Zung | CDO | A | +135,000 deriv. | — |
| 2025-05-22 | Marc Rubin | Director | A | +14,400 deriv. | — |
| 2025-05-22 | Anne Elizabeth Borgman | Director | A | +14,400 deriv. | — |
| 2025-05-22 | Diantha Duvall | CFO | A | +135,000 deriv. | — |
| 2025-05-22 | John Hohneker | Director | A | +14,400 deriv. | — |
| 2025-05-05 | Ahmed MD Hamdy | CMO | A | +200,000 deriv. | — |
| 2025-01-30 | Diantha Duvall | CFO | A | +15,000 deriv. | — |
| 2025-01-30 | John Hohneker | Director | A | +1,600 deriv. | — |
| 2025-01-30 | James E Dentzer | President & CEO | A | +40,000 deriv. | — |
| 2025-01-30 | Anne Elizabeth Borgman | Director | A | +1,600 deriv. | — |
| 2025-01-30 | Kenneth I Kaitin | Director | A | +1,600 deriv. | — |
| 2025-01-30 | Martyn D Greenacre | Director | A | +1,600 deriv. | — |
| 2025-01-30 | Jonathan B. Zung | CDO | A | +15,000 deriv. | — |
| 2025-01-30 | Marc Rubin | Director | A | +1,600 deriv. | — |
| 2024-05-23 | Diantha Duvall | CFO | A | +39,000 deriv. | — |
| 2024-05-23 | Jonathan B. Zung | CDO | A | +40,700 deriv. | — |
| 2024-05-23 | James E Dentzer | President & CEO | A | +100,000 deriv. | — |
| 2024-05-23 | Marc Rubin | Director | A | +4,250 deriv. | — |
| 2024-05-23 | Martyn D Greenacre | Director | A | +4,250 deriv. | — |
| 2024-05-23 | Anne Elizabeth Borgman | Director | A | +4,250 deriv. | — |
| 2024-05-23 | Kenneth I Kaitin | Director | A | +4,250 deriv. | — |
| 2024-05-23 | John Hohneker | Director | A | +4,250 deriv. | — |
| 2023-05-03 | Jonathan B. Zung | CDO | A | +500,000 deriv. | — |
| 2023-01-24 | Marc Rubin | Director | A | +85,000 deriv. | — |
| 2023-01-24 | Robert Martell | Head of Research & Development | A | +350,000 deriv. | — |
| 2023-01-24 | James E Dentzer | President & CEO | A | +1,000,000 deriv. | — |
| 2023-01-24 | Martyn D Greenacre | Director | A | +85,000 deriv. | — |
| 2023-01-24 | Diantha Duvall | CFO | A | +500,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| James E Dentzer | President & CEO | 7,436 | $2.81K |
| Diantha Duvall | CFO | 3,885 | $1.47K |
| Ahmed MD Hamdy | CMO | 3,333 | $1.26K |
| Jonathan B. Zung | CDO | 3,333 | $1.26K |
| Marc Rubin | Director | 1,405 | $530 |
| Kenneth I Kaitin | Director | 570 | $215 |
| Martyn D Greenacre | Director | 65 | $25 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRIS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.